Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease
Blocking a liver protein could lower risks for fatty liver disease patients
This meta-analysis of data from the Quebec Obesity Biobank used integrated proteogenomic analysis and Mendelian randomization to assess caus…
A massive analysis suggests blocking a specific liver protein might reduce risks for fatty liver disease, cirrhosis, and cancer while improv…
IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression
IGFBP proteins play opposite roles in liver disease progression
This narrative review synthesizes evidence on insulin-like growth factor-binding proteins (IGFBPs) in metabolic dysfunction-associated steat…
A review shows specific IGFBP proteins can protect the liver or drive damage depending on the stage of disease and which protein is involved…
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
General obesity, central obesity, and high triglycerides increase risk of precancerous polyps in colorectal cancer surveillance
Metabolic health matters for colon cancer risk in high-risk surveillance patients
This meta-analysis of 24 observational studies found that metabolic factors such as general obesity, central obesity, hypertension, and high…
Metabolic issues like obesity and diabetes raise the risk of precancerous polyps in people at higher risk for colon cancer. This analysis of…
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
This systematic review and meta-analysis of 212,618 participants from observational studies found that higher TyG index levels were associat…
A large analysis found that higher TyG index levels are tied to increased odds of non-alcoholic fatty liver disease. This simple blood test …
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…
Systematic Review: Flavonoids from Traditional Chinese Medicine Show Promise for NAFLD
Flavonoids from Chinese medicine show promise for fatty liver disease
This systematic review examines flavonoids from traditional Chinese medicine for non-alcoholic fatty liver disease. The authors report that …
A systematic review suggests flavonoids from traditional Chinese medicine may improve liver health in humans and animals by reducing fat and…
Narrative review explores immunometabolic networks in MASH and MASLD
Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes
Palmitoleic Acid Shows Mixed Links to Metabolic Health
This narrative review examines palmitoleic acid (POA) supplementation and food matrices regarding insulin resistance, fatty liver, and hyper…
Higher palmitoleic acid levels are tied to fatty liver and insulin resistance, but supplements show neutral effects.
Bayesian network meta-analysis of drugs for pediatric NAFLD steatosis improvement
New analysis shows specific drugs help children with fatty liver disease improve liver health and lower body weight
This Bayesian network meta-analysis evaluated drugs in pediatric NAFLD patients confirmed by ultrasound or biopsy. The review synthesized da…
A large review of 1,582 children found that certain medicines helped reduce liver fat and improve blood markers. Energy-focused drugs were b…
Systematic Review of Schisandra chinensis for Metabolic Dysfunction-Associated Steatotic Liver Disease
Ancient herb shows promise for fatty liver disease
This systematic review summarizes preclinical evidence on Schisandra chinensis Fructus (SCF) and its metabolites for metabolic dysfunction-a…
A systematic review finds Schisandra chinensis may protect the liver and reduce fat buildup, but evidence is still early.
Questions about Metabolic Dysfunction-Associated Steatotic Liver Disease
Can specific genetic variants change the risk of metabolic problems in MASLD?
Yes, specific genetic variants like PNPLA3-I148M and PON1 variants can increase the risk of metabolic problems and liver damage in MASLD.
Full answer →Can chiglitazar help reduce liver fat in MASLD patients with high triglycerides?
Yes, a phase II trial found chiglitazar significantly reduced liver fat in MASLD patients with high triglycerides and insulin resistance.
Full answer →Are there natural herbal plants that target autophagy for Metabolic-Associated Fatty Liver Disease?
Research suggests natural herbal plants can target autophagy pathways in Metabolic-Associated Fatty Liver Disease, offering a multi-target approach that may be safer than single-drug therapies.
Full answer →Does curcumin help reduce weight in Metabolic-Associated Fatty Liver Disease patients?
Curcumin helps reduce weight in Metabolic-Associated Fatty Liver Disease patients but does not significantly change BMI or waist circumference.
Full answer →Can bile acid regulation help with MASLD liver fibrosis?
Regulating bile acids can help treat MASLD liver fibrosis because these chemicals directly activate cells that cause scarring and disrupt liver function.
Full answer →Are there any validated treatments for metabolic dysfunction-associated fatty liver disease mentioned in recent reviews?
Recent reviews highlight lifestyle changes and emerging drugs like resmetirom, but no universally validated treatment exists yet for MASLD.
Full answer →What specific outcomes are currently known about metabolic dysfunction-associated fatty liver disease from recent reviews?
Recent reviews show MASLD is the leading cause of chronic liver disease, drives liver transplant needs, and involves complex links between gut bacteria, circadian rhythms, and mitochondrial function.
Full answer →Can machine learning models help doctors diagnose my metabolic dysfunction-associated steatotic liver disease?
Yes, machine learning models can help diagnose MASLD and predict complications like liver cancer, with studies showing high accuracy (up to 91%) for detecting fatty liver on ultrasound and predicting HCC risk.
Full answer →All Metabolic Dysfunction-Associated Steatotic Liver Disease Articles
- Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
- MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease
- IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression
- Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
- General obesity, central obesity, and high triglycerides increase risk of precancerous polyps in colorectal cancer surveillance
- Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
- GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
- Systematic Review: Flavonoids from Traditional Chinese Medicine Show Promise for NAFLD
- Narrative review explores immunometabolic networks in MASH and MASLD
- Narrative review of palmitoleic acid links to metabolic health and fatty liver outcomes
- Bayesian network meta-analysis of drugs for pediatric NAFLD steatosis improvement
- Systematic Review of Schisandra chinensis for Metabolic Dysfunction-Associated Steatotic Liver Disease
- Narrative review explores macrophage reprogramming for liver fibrosis and MASH
- Systematic review of Dendrobium phenanthrene bioactivity across multiple disease models
- Pediatric Gut Microbiome Links to Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes
- Meta-analysis finds no significant difference in Lp(a) levels in MASLD patients vs controls
- Meta-analysis shows curcumin reduces weight but lacks impact on BMI or waist circumference in metabolic fatty liver disease patients
- Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
- Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis
- Metabolic dysfunction-associated steatotic liver disease patients with advanced fibrosis face high hepatocellular carcinoma risk over ten years
- Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
- Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
- Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
- Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation grading
- Systematic review finds weak link between atypical antipsychotics and MASLD in youth
- Essential phospholipids reduced hepatic steatosis and improved HbA1c in patients with MASLD and type 2 diabetes over 6 months
- Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
- Plasma homocysteine levels associated with increased risk of incident metabolic dysfunction-associated steatotic liver disease
- Narrative review links ultra-processed food to obesity and multiple metabolic conditions
- Elevated free and bioavailable testosterone linked to non-alcoholic fatty liver disease risk in postmenopausal women
- Review of scRNA-seq applications in non-alcoholic fatty liver disease and hepatocellular carcinoma research
- Narrative review of phytochemicals in zebrafish models for metabolic dysfunction-associated steatotic liver disease and related conditions
- Narrative review explores gut metabolites postbiotics obesity fatty liver and bone loss associations
- Ketotifen shows significant improvements in hepatic steatosis and fibrosis indices compared with vitamin E in a pilot study of NAFLD
- Systematic review finds gut microbiota drugs reduce liver enzymes in MASLD patients compared to placebo
- High aMAP Risk Scores Associated With Increased Mortality in Metabolic and Alcohol-Related Liver Disease
- Biochemical remission of Cushing's syndrome reduces hepatic steatosis and fibrosis indices in adult patients
- Narrative Review Suggests Electroacupuncture May Benefit NAFLD with Minimal Side Effects
- Narrative review links microgravity exposure to altered fat distribution and inflammation in metabolic disease models
- Meta-analysis shows salidroside improves metabolic markers in rodent NAFLD models
- Systematic review links periodontitis to NAFLD progression and HCC risk
- Higher ZJU index associated with worse metabolic profiles in adults with type 2 diabetes and hyperuricemia
- Meta-analysis compares FAST and MAST scores for MASH with significant fibrosis diagnosis
- Transcriptomic signature distinguishes MASL from MASH using neural network model
- Non-traditional lipid indices associate with coronary heart disease risk in MASLD and type 2 diabetes patients
- Pathophysiological review explores platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepatitis and steatotic liver disease
- GNRI, CONUT, and PNI indices predict metabolic-associated fatty liver disease in Chinese adults
- IGFBP2 as a context-dependent regulator of metabolic dysregulation in obesity and type 2 diabetes
- Narrative review covers IBD, bile acid malabsorption, IBS-D, CRC, obesity, NAFLD, and sepsis-related intestinal injury
- Retrospective analysis evaluates CT and MRI fat quantification for diagnosing metabolic dysfunction–associated steatotic liver disease
- Literature review synthesizes Schisandra chinensis effects on gut microbiota and metabolic pathways across multiple conditions
- Narrative review explores miRNA signalling versus conventional RNA therapeutics in metabolic dysfunction-associated steatotic liver disease
- Observational study maps sex-specific molecular architectures in MASLD using multi-omics profiling
- Observational study links semaglutide dose and weight loss to lower liver disease risk
- Systematic review and meta-analysis of puerarin in experimental non-alcoholic fatty liver disease models
- Narrative review examines natural herbal therapeutics targeting autophagy in metabolic-associated fatty liver disease
- Meta-analysis of efruxifermin shows significant liver benefits in NASH/MASH patients with short follow-up
- Narrative review synthesizes evidence on NAFLD, NASH, and viral hepatitis management without reported trial data
- Review of liver disease immunomodulation strategies notes precision over broad suppression
- Review of MASLD without reported population data or specific outcomes
- Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
- Narrative review estimates global MASLD prevalence at 38% and notes it surpassed viral hepatitis as China's leading cirrhosis cause
- PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
- Review of bile acid homeostasis regulation in liver disease and cancer
- Dihydromyricetin reduces hepatic lipids and improves metabolic markers in murine MASLD models
- Meta-analysis finds exercise training reduces intrahepatic lipids and improves metabolic markers in NAFLD
- Systematic review shows PCOS in obese women links to high MASLD and 2–4 fold increased cardiovascular and diabetes risks
- Review of quercetin in metabolic diseases shows promise but lacks clinical validation
- Higher fasting glucose-to-HDL ratio associated with increased MASLD risk in non-diabetic Japanese adults
- Vitamin D supplementation associated with improved metabolic markers in patients with Metabolic-Associated Fatty Liver Disease
- Adipose-inflammatory factors elevated in obese children, correlate with metabolic health and NAFLD severity
- Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
- Meta-analysis finds fatty pancreas disease in over half of adults with MASLD
- Hyperferritinemia is associated with higher liver-related event incidence in patients with metabolic dysfunction-associated steatotic liver disease
- Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
- Hepatic steatosis compromises APRI and FIB-4 accuracy for staging fibrosis in chronic hepatitis B patients
- In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population
- PFAS exposure linked to sex-specific steroid hormone disruption in MASLD patients
- Review examines IL-33/ST2 signaling role in MASLD pathophysiology and potential clinical utility
- Walking program improves liver enzymes and BMI in children with PKU and NAFLD
- Review explores L-carnitine mechanisms for MASLD, a condition affecting over one-third globally
- Meta-analysis links ultra-processed food consumption to increased MASLD risk in 1.2 million participants
- Meta-analysis links elevated atherogenic index of plasma to increased fatty liver disease risk
- Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
- Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
- Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
- High Dietary Inflammatory Index Linked to Increased NAFLD Risk (OR 1.33, CI 1.23-1.44)